Partnership for Part D Access
  • Home
  • About Us
    • Who We Are
    • Patient Communities
    • Our Leadership
  • The Issue
    • Six Protected Classes
    • History
  • Resources
  • Newsroom
  • Stakeholder Voices
  • Contact Us
  • Home
  • About Us
    • Who We Are
    • Patient Communities
    • Our Leadership
  • The Issue
    • Six Protected Classes
    • History
  • Resources
  • Newsroom
  • Stakeholder Voices
  • Contact Us

Resources

Partnership Submits Letter on HHS Drug Pricing RFI

7/17/2018

 
Picture
In a letter responding to the Department of Health and Human Services drug pricing request for information (RFI), the Partnership for Part D access outlined the overwhelming evidence that reinforces the importance of the ‘six protected classes’ as they currently stand. Despite widespread bipartisan backing and a history of longstanding support from patients, this new proposal designed to address prescription drug prices could potentially undermine Medicare's vital 'protected classes' policy. Partnership's letter to HHS emphasizes that the six protected classes policy is an essential patient safeguard in Part D, and stand as a guarantee that patients with the most complex conditions will have access to the full spectrum of medications under Part D.

The letter in its entirety can be read below. 
partnership_for_part_d_access_-_drug_pricing_blueprint_rfi_comments.pdf
File Size: 311 kb
File Type: pdf
Download File


Comments are closed.

    Author

    Write something about yourself. No need to be fancy, just an overview.

    Archives

    March 2021
    February 2021
    November 2020
    January 2020
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    November 2018
    July 2018
    June 2018
    March 2018
    January 2018
    September 2017
    August 2016
    June 2016
    March 2016
    September 2014
    March 2014
    February 2014
    January 2014
    July 2011
    September 2010
    March 2010
    July 2008
    January 2008
    December 2003

    Categories

    All

    RSS Feed

Learn more

About Us
Patient Communities
​Issues
​Background

What's New?

​Newsroom
Resources
​

Contact

Contact Us
E-Mail 
© COPYRIGHT 2018. ALL RIGHTS RESERVED.